Pancreatic carcinoma

Lancet

Volumn 349, Issue 9050, 1997, Pages 485-489

  Rosewicz, Stefan ^a   Wiedenmann, Bertram ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER STAGING; DIAGNOSTIC IMAGING; HUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; RISK FACTOR; SHORT SURVEY;

EID: 0031054695     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)05523-7     Document Type: Review

References (29)

1. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. N Engl J Med 1993; 328: 433-37.
2. Gullo L, Pezzilli R, Morselli-Labate AM and the Italian Pancreatic Cancer Study Group. Diabetes and the risk of pancreatic cancer. N Engl J Med 1994; 331: 81-84.
3. Klöppel G. Pathology of nonendocrine tumors. In: Go VLW, Di Magno EP, Gardner JD, Lebenthal E, Reber HA, Scheele GA, eds. The pancreas. New York: Raven, 1993: 871-97.
4. Hruban RH, van Mansfield AD, Offerhaus GJ, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas: a study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993; 143: 549-54.
5. Kalthoff H, Schmiegel W, Roeder C, et al. p53 and K-ras alterations in pancreatic epithelial cell lesions. Oncogene 1993; 8: 289-98.
6. Bartz C, Ziske C, Wiedenmann B, Mölling K. p53 tumour suppressor gene expression in human pancreatic neuroendocrine carcinomas. Gut 1996; 38: 403-09.
7. Hahn SA, Schutte M, Shamshul Hoque ATM, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271: 350-53.
8. Kalser MH, Barkin J, MacIntyre JM. Pancreatic cancer: assessment of prognosis by clinical presentation. Cancer 1985; 56: 397-402.
9. Freeny PC, Traverso WL, Ryan JA. Diagnosis and staging of pancreatic adenocarcinoma with dynamic computed tomography. Am J Surg 1991; 165: 600-06.
10. Fuhrman GM, Charnsangavej C, Abbnizzese JL, et al. Thin-section, contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994; 167: 104-13.
11. Kubota Y, Takaoka M, Tani K, et al. Endoscopic transpapillary biopsy for diagnosis of patients with pancreatobiliary structures. Am J Gastroenterol 1993; 70: 276-84.
12. Tio TL, Sie LH, Tytgat GNJ. Endosonography and cytology in diagnosing and staging pancreatic body and tail carcinoma. Dig Dis Sci 1993; 38: 59-64.
13. Rashleigh-Belcher HJC, Russell RCG, Lees WR. Cutaneous seeding of pancreatic carcinoma by fine-needle aspiration biopsy. Br J Radiol 1986; 59: 182-83.
14. Rösch T, Braig C, Gain T, et al. Staging of pancreatic and ampullary carcinoma by endoscopic ultrasound. Gastroenterology 1992; 102: 188-99.
15. Warshaw AI. Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg 1991; 161: 26-30.
16. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994; 331: 1116-21.
17. Tada M, Omata M, Kawai S, et al. Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 1994; 53: 2472-74.
18. Tada M, Ohashi M, Shiratori Y, et al. Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. Gastroenterology 1996; 110: 227-31.
19. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 1995; 221: 721-31.
20. Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy: 118 consecutive resections without an operative mortality. Ann Surg 1990; 211: 447-58.
21. Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991; 161: 120-25.
22. Baumel H, Hugier M, Manderscheid JC, Fabre JM, Houry S, Fagot H. Results of resection for cancer of the exocrine pancreas: a study from the French Association of Surgery. Br J Surg 1994; 81: 102-07.
23. Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CG. Resection margins in carcinoma of the head of the pancreas: implications for radiation therapy. Ann Surg 1993; 217: 144-48.
24. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (600 rads) radiation alone, moderate dose radiation (4000 rads+5 fluorouracil), and high dose radiation+5-fluorouracil: the Gastrointestinal Tumor Study Group. Career 1981; 48: 1705-10.
25. Lionetto R, Pugliese V, Bruzzi P, Rosso R. No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 1995; 31A: 882-87.
26. Rothenberg ML, Burris HA III, Andersen JS, et al. Gemcitabine: effective palliative therapy for pancreas cancer patient failing 5-FU. Proc Am Soc Clin Oncol 1995; 14: 198.
27. Shepherd HA, Royle G, Ross APR, et al. Endoscopic biliary endoprothesis in the palliation of malignant obstruction of the distal common bile duct: a randomized trial. Br J Surg 1988; 75: 1166-69.
28. Bornman PC, Harries-Jones EP, Tobias R, et al. Prospective controlled trial for transhepatic biliary endoprosthesis versus bypass surgery for incurable carcinoma of the head of the pancreas. Lancet 1986; i: 69-71.
29. Proctor HJ, Mauro M. Biliary diversion for pancreatic carcinoma: matching the methods and the patient. Am J Surg 1990; 159: 67-71.